Health care stocks were mixed pre-bell Monday, with the Health Care Select Sector SPDR Fund (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) 0.4% higher.

Jazz Pharmaceuticals (JAZZ) shares were up more than 21% after the company said its phase 3 trial evaluating Ziihera plus chemotherapy as a first-line treatment in gastroesophageal adenocarcinoma showed a statistically significant improvement in progression-free survival compared with trastuzumab and chemotherapy.

Surmodics (SRDX) stock was up nearly 3% after the company said it expects to close its sale to an affiliate of GTCR promptly after the Federal Trade Commission and certain states told a federal court they won't appeal the denial of a bid to block the deal.

Immatics (IMTX) shares were down nearly 1% after the company reported a wider Q3 net loss as revenue fell during the period.